BiotechTubeBiotechTube
Home/Pipeline/ARV-027

ARV-027

Breast Cancer

Phase 1Active

Key Facts

Indication
Breast Cancer
Phase
Phase 1
Status
Active
Company
Arvinas

About Arvinas

Arvinas is a leader in the field of targeted protein degradation, founded on groundbreaking research from Yale University. The company's PROTAC® platform enables the development of therapeutics that harness the body's natural protein disposal system to degrade disease-causing proteins, potentially addressing previously 'undruggable' targets. With multiple clinical-stage assets, strategic partnerships, and a robust discovery engine, Arvinas aims to revolutionize treatment for serious diseases in oncology and neurology.

View full company profile

Therapeutic Areas

OncologyNeurology

Other Breast Cancer Drugs

DrugCompanyPhase
Verzenio (abemaciclib)Eli LillyApproved
Pan-mutant-selective PI3Kα inhibitorNovartisAcquisition
TrodelvyRoyalty PharmaCommercial
Trastuzumab biosimilar (IBI306)Innovent BiologicsPhase 3
Ogivri (trastuzumab biosimilar)ViatrisApproved
Trastuzumab BiosimilarDr. Reddy's LaboratoriesApproved
Biosimilar TrastuzumabCiplaCommercial
Ogivri (Trastuzumab)BioconApproved
TamoxifenNatco PharmaApproved
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials
ATNM-400Actinium PharmaceuticalsPreclinical